NCT05847920

Efficacy and Safety of SHR-2010 Injection in the Treatment of Primary IgA Nephropathy

A Phase II Seamless Design, Randomized, Double-blind, Placebo-controlled, Dose-exploration Study Evaluate the Efficacy and Safety of SHR-2010 Injection in Patients With Primary IgA Nephropathy

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 53 (actual)
• Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The study is being conducted to evaluate the efficacy, and safety of SHR - 2010 injection in patients with primary IgA nephropathy.

Conditions

• Primary IgA Nephropathy

Interventions

Type	Name	Description
DRUG	SHR-2010 Injection	SHR-2010 Injection
DRUG	Placebo	Placebo

Timeline

• Start date: 2023-06-04
• Primary completion: 2025-01-20
• Completion: 2025-01-20
• First posted: 2023-05-08
• Last updated: 2025-03-05

Locations

1 site across 1 country: China